Portal hypertension is a condition characterized by increased blood pressure within the portal venous system, commonly caused by cirrhosis, which accounts for 80%-90% of cases. According to the portal hypertension pipeline analysis by Expert Market Research, the condition is driving focused research and development in novel therapeutics. The drug pipeline includes vasodilators, beta-blockers, and innovative agents targeting portal pressure reduction. With growing awareness, improved diagnostics, and advancements in pharmacological interventions, the pipeline is expected to witness significant growth in the coming years. The increasing prevalence of liver diseases is further fueling the demand for effective portal hypertension therapeutics.
Major companies involved in the portal hypertension pipeline analysis include Galectin Therapeutics Inc., Onyx Therapeutics, Inc., and others.
Leading drugs currently in the pipeline include Zinc Acexamate, Alverine, and others.
Rising clinical focus on nitric oxide modulation and antifibrotic therapies is driving significant momentum in portal hypertension drug development, with several candidates progressing through advanced clinical stages.
The Portal Hypertension Pipeline Analysis Report by Expert Market Research gives comprehensive insights into portal hypertension therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for portal hypertension. The portal hypertension report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The portal hypertension pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with portal hypertension treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to portal hypertension.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Portal hypertension is a condition where there is increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. It occurs when there is obstruction or resistance to blood flow through the liver, often due to liver cirrhosis, leading to the development of collateral veins and complications such as varices and ascites.
Portal hypertension treatment includes the transjugular intrahepatic portosystemic shunt (TIPS) procedure, which diverts blood flow within the liver to decrease pressure in the portal vein and manage associated risks. In the drug pipeline, current approaches aim to control portal pressure using non-selective beta-blockers while also exploring minimally invasive interventions like TIPS to reduce the risk of serious outcomes.
The drug pipeline for portal hypertension is evolving to address its growing clinical burden. According to a 2024 review, cirrhosis, the primary cause, accounted for 2.4% of global deaths in 2019. The age-standardised global prevalence reached 1.4%, highlighting a significant need for effective treatments. Ongoing research and development efforts focus on novel therapeutic targets to prevent hepatic decompensation and reduce mortality associated with this high-risk condition.
This section of the report covers the analysis of portal hypertension drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, in the portal hypertension clinical trials, phase II holds the largest share with 40%, reflecting strong innovation and early efficacy signals. Phase III follows at 34.29%, showing promising advancements toward regulatory approval. Phase IV contributes 22.86%, highlighting post-marketing validation, whereas early phase I represents 2.86%. These developments positively impact market growth, ensuring a robust future for treatment options.
The drug molecule categories covered under the portal hypertension pipeline analysis include small molecules, biologics, peptides, RNA-based therapies, gene therapies, and others. The portal hypertension report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for portal hypertension.
Carbohydrate-based galectin inhibitors are gaining traction as a novel drug class in the portal hypertension pipeline. For instance, Belapectin, developed by Galectin Therapeutics, is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that targets the galectin-3 protein involved in fibrosis and inflammation. In the NAVIGATE trial, Belapectin showed a significant 68.1% reduction in new varices among U.S. patients with cirrhosis and portal hypertension, demonstrating promising therapeutic potential.
The EMR report for the portal hypertension pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed portal hypertension therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in portal hypertension clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for portal hypertension. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of portal hypertension drug candidates.
Zinc Acexamate is being evaluated in a Phase III trial sponsored by Hospital Universitari Vall d'Hebron Research Institute. This randomized, double-blind study is enrolling 300 patients to assess whether zinc supplementation improves prognosis in compensated advanced chronic liver disease. Zinc Acexamate is believed to enhance liver function, stabilize zinc homeostasis, reduce inflammation, and protect hepatocytes, potentially delaying decompensation and portal hypertension complications.
Alverine, supported by Shanghai Changzheng Hospital, is currently undergoing a Phase II/III clinical trial to evaluate its safety and efficacy in treating cirrhotic portal hypertension. This study is examining Compound Alverine Citrate Capsules, combining 60 mg Alverine Citrate and 300 mg Simethicone. The drug is known for relaxing gut muscles and interacting with 5-HT receptors.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Portal Hypertension Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for portal hypertension. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into portal hypertension collaborations, regulatory environments, and potential growth opportunities.
Hypertension Drug Pipeline Analysis Report
Global Home Blood Pressure Monitoring Devices Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share